Evidence map›Paper›PMID 24856029›Full record

ReviewLancet (London, England)2014

Rare inherited kidney diseases: challenges, opportunities, and perspectives.

Olivier Devuyst, Nine V A M Knoers, Giuseppe Remuzzi, Franz Schaefer, Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Lancet (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 4 pooled it
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 4 syntheses or guidelines pooled it, 237 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Fifty Shades of Risk: Population Studies and the Genetic Architecture of Kidney Diseases.Journal of the American Society of Nephrology : JASN · 2026
    Review
  10. Review
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

Olivier DevuystDivision of Nephrology, Université catholique de Louvain, Brussels, Belgium; Institute of Physiology, Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland. Electronic address: olivier.devuyst@uzh.ch.
Nine V A M KnoersDepartment of Medical Genetics, Division of Biomedical Genetics, University Medical Centre Utrecht, Utrecht, Netherlands.
Giuseppe RemuzziIRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso and Unit of Nephrology and Dialysis, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Franz SchaeferPediatric Nephrology Division, Center for Pediatric and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Board of the Working Group for Inherited Kidney Diseases of the European Renal Association and European Dialysis and Transplant Association
Swiss Integrative Center for Human Health · CHUniversity Hospital Heidelberg · DEUniversity Medical Center Utrecht · NL

Funding

Pediatric investigation for genetic factors linked to renal progression (PediGFR)R01DK082394 · NIDDK · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI WONG, CRAIG S. · 2010 to 2013
$2.2M
NIDDK NIH HHS R01 DK082394
6 · The paper itself

Abstract

At least 10% of adults and nearly all children who receive renal-replacement therapy have an inherited kidney disease. These patients rarely die when their disease progresses and can remain alive for many years because of advances in organ-replacement therapy. However, these disorders substantially decrease their quality of life and have a large effect on health-care systems. Since the kidneys regulate essential homoeostatic processes, inherited kidney disorders have multisystem complications, which add to the usual challenges for rare disorders. In this review, we discuss the nature of rare inherited kidney diseases, the challenges they pose, and opportunities from technological advances, which are well suited to target the kidney. Mechanistic insights from rare disorders are relevant for common disorders such as hypertension, kidney stones, cardiovascular disease, and progression of chronic kidney disease.

Indexed as

AnimalsDisease Models, AnimalGenetic Diseases, InbornHeterozygoteHumansKidney DiseasesRare DiseasesRenal Replacement Therapy

Identifiers

PMID24856029
PMCPMC4135047
OpenAlexW2051718666

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.